 |
 |
|||||||||||||||
 |
||||||||||||||||
|
||||||||||||||||
|
||||||||||||||||
|
Intravenous Administration In Combination With Docetaxel - United Kingdom In August 2008, Oncolytics announced that it had completed the dose escalation portion in a clinical trial in the U.K. using intravenous administration of REOLYSIN® in combination with docetaxel. The primary objective of the trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended dose and dosing schedule and safety profile of REOLYSIN® when administered in combination with docetaxel. Secondary objectives include the evaluation of immune response to the drug combination, the body's response to the drug combination compared to chemotherapy alone and any evidence of anti-tumour activity. See related press releases and documents: August 11, 2008 - Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN®/Docetaxel Trial July 23, 2007 - Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN®/Docetaxel trial January 3, 2007 - Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN® in Combination with Docetaxel |
|
|||||||||||
 |
|
 |